INC Research, Inc. Discusses Benefits of Involving CROs Early in Planning at Partnerships in Clinical Trials 2012
“We’re excited to be taking part again in this year’s Partnerships in Clinical Trials,” said Alistair Macdonald, President, Clinical Development Services, and head of the Company’s European operations. “Europe continues to be an important region for clinical research, particularly in the areas of oncology, CNS, cardiology, and endocrinology, which are currently experiencing significant growth in the region. By having locally-based teams with strong regional knowledge of every European country, we can engage our customers earlier in the product lifecycle to offer more insightful strategies that ultimately speed their products to market. And if customers are looking beyond Europe, our global footprint also enables us to deliver high-quality clinical development service anywhere in the world.”
The continued shift in the biopharmaceutical company-CRO relationship from project-specific outsourcing to clinical delivery strategic alliances has made it easier for drug developers to benefit from CROs as innovation partners. Multi-year strategic alliances include more input from the CRO and leverage years of perspective, expertise and tactical approaches. These strategic alliances enable CROs to focus more deeply on the commercial and regulatory viability of compounds much earlier in the drug development lifecycle.
INC Research Speaker
INC Research is pleased to once again contribute thought leadership to the agenda for the Partnerships in Clinical Trials conference, with Manfred Weiler, PhD, Senior Vice President, Europe & Asia Pacific Business and Alliance Development presenting on the benefits of involving CROs early in planning. Specifically, he will explore the importance of involving CROs at the pre-protocol stage, how to exploit best practices from a CRO, and how to determine the level of involvement with CROs that works best for individual projects. Dr. Weiler’s session, “Benefits of involving your CRO early in planning,” will be held on Nov. 7 at 3:45 p.m.
Additionally, INC Research executives will be on hand to discuss recent developments in:
• Strategic alliances – Evaluate innovative and flexible partnership models that enable customers to quickly and efficiently assess product potential and accelerate their delivery to market.
• Conducting trials in Europe – Examine the latest considerations and regional nuances for clinical research in fast-growing therapeutic areas like oncology, CNS, cardiovascular, and endocrinology.
• Metrics-driven methodologies – Achieve high-quality results, including faster study start-up times, patient enrollments and database locks, through globally harmonized standardized operating procedures at every clinical trial stage through our Trusted Process®, a proprietary approach to clinical development.
• Data-Driven Intelligence and Decision Making – An innovative approach to data, applied at the patient, study, program and sponsor level, leads to efficiencies in study start-up and patient recruitment and enables a risk-based monitoring approach.
With global experience in more than 100 countries and the extensive therapeutic expertise to work in nearly any indication, INC Research is a leader in developing innovative and flexible strategic alliances that enable customers to quickly and efficiently assess product potential. From full-service strategic partnerships to functional service provider (FSP) alliances, networked drug development to niche solutions tailored to individual customer needs, INC Research can advise customers on the development model that best fits their unique requirements. INC Research has a strong track record in Europe where the Company has run trials in every European country, including those in Central and Eastern Europe.
For more information about INC Research's capabilities for conducting clinical trials in Europe, please visit booth #709 at Partnerships in Clinical Trials or download our European capabilities brochure. Customers interested in contacting INC Research can reach us in Europe at +44 1276 4810000 or at info@incresearch.com.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685